LifePharm® Global Network or LPGN, makers of Laminine Food Supplements has released data based on a clinical study on DIGESTIVE+++ food supplement. The four-week analysis was performed by LPGN’s lead scientists, Dr. Edward Andujar and Dr. Hitendra Shah at the Wellness Clinic in Diamond Bar City, California in September 17, 2016.
Volunteer subjects consumed two DIGESTIVE+++ c capsules and two Laminine® capsules daily for four weeks. At the end of the four-week period, participants showed a significant improvement in several indicators of gut health, most notably in “butyrate,” a short chain fatty acid (SCFA). The fatty acids (consisting of acetate, propionate and butyrate) serve several important functions to the digestive tract and gut lining.
Participants were asked to refrain from using other supplements prior to the Wellness Clinic study and provided the doctors with initial baseline stool samples. The conclusive data from the Comprehensive Digestive Stool Analysis (Genova Diagnostics, Asheville, North Carolina) showed a substantial improvement in total Short Chain Fatty Acids (SCFAs).
Can the number of participants enough to conclude the efficacy of the product?
Although the data is conclusive on the part of LifePharm who manufactures the product, it is noteworthy to consider that the study has limited participants at only four weeks of study. While it reveals positive effects, other studies should be established at a later date.
LifePharm Research Scientist Dr. Edward Andujar said “The increase of the SCFAs— particularly butyrate, which is the most beneficial and saw a 28 percent increase in production—is a definite indicator that the gut is reestablishing healthier microbiota. In certain imbalances of the colon and GI tract, butyrate has shown decreased inflammation of the bowel and kept cells lining the colon properly nourished.”
…butyrate has shown decreased inflammation of the bowel and kept cells lining the colon properly nourished
DIGESTIVE+++ is the proprietary formula of LifePharm, and has been on the market since November 2014. The ingredients in the product contain a specialized prebiotic blend, probiotic and comprehensive enzyme blend to aid in optimal nutrient absorption. Although this is the company’s first clinical study on the DIGESTIVE+++ supplement, there is much research on the beneficial aspects of the individual ingredients. Countless individuals have also provided endorsements revealing their digestion, weight and overall GI health has vastly improved since consuming DIGESTIVE+++.
According to LifePharm Product Development Researcher Kimberly Lloyd, “Consuming prebiotics and probiotics such as fructooligosaccharides and Bacillus coagulans, which are found in the DIGESTIVE+++ formula, support many factors relating to gut health. We’re highly encouraged by the results of the study and confident the supplements are aiding SCFAs to enhance healthy gut flora.”
Are there independent probiotics and prebiotics studies that supports LifePharm’s claims?
While the study is promising, we can conclude that the product works, but does it on a wider circumspect? While the study was done openly, the people behind the trial are also the sellers of the products, thus the desired outcome may not be objective, since after all, LifePharm would want to sell its product.
NCBI has published several white papers on metabolic disorders and a simple google can give you very positive results with little side effects if any. LifePharm’s DIGESTIVE+++ is not limited to metabolic or gut health as studies are showing how the digestive system affects the rest of bodily functions, particularly the immune system.
Therefore, while the study published for this product may appear self-serving, the ingredients of DIGESTIVE+++ do have positive effects and no side effects to date. But then, it would be just like other probiotics in the market. What is interesting is how users who also took LifePharm’s flagship product Laminine and DIGESTIVE together claim life-changing results in their Laminine testimony.
Probiotic & Prebiotic supplement helps heart and diabetic patients
A recent independent study was published in NCBI have concluded that intestinal microbiota may play an important role in the pathogenesis of T2DM (type 2 Diabetes) and CVD (Cardiovascular disease) by influencing body weight, pro-inflammatory activity, and insulin resistance. Gut microbiota composition and function can be regulated via probiotics and prebiotics thus numerous studies have indicated that probiotics and prebiotics affect T2DM and CVD by changing gut microbiota, regulating insulin signaling, and lowering cholesterol. (Source: NCBI Probiotics & Prebiotics)
In addition to DIGESTIVE+++ and Laminine, LifePharm produces two other supplements, Laminine OMEGA+++ and LifePharm IMMUNE+++ exclusively manufactured in the U.S.A. Clinical studies have also been conducted on Laminine and IMMUNE+++ with equally encouraging results.
For more information, please contact:
Steve Brown, Vice President of Field Development
949-216-9600 ext. 317